SAREPTA THERAPEUTICS INC (SRPT) Stock Price, Quote, News and Overview
NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD
SRPT Quote, Performance and Key Statistics
36.2
-0.17 (-0.47%)
The current stock price of SRPT is 36.2 USD. In the past month the price decreased by -33.74%. In the past year, price decreased by -72.45%.
SRPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About SRPT
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Company Info
SAREPTA THERAPEUTICS INC
215 1st St Ste 415
Cambridge MASSACHUSETTS 02142 US
CEO: Douglas S. Ingram
Employees: 1372
Phone: 16172744000
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the stock price of SAREPTA THERAPEUTICS INC today?
The current stock price of SRPT is 36.2 USD. The price decreased by -0.47% in the last trading session.
What is the ticker symbol for SAREPTA THERAPEUTICS INC stock?
The exchange symbol of SAREPTA THERAPEUTICS INC is SRPT and it is listed on the Nasdaq exchange.
On which exchange is SRPT stock listed?
SRPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SAREPTA THERAPEUTICS INC stock?
31 analysts have analysed SRPT and the average price target is 151 USD. This implies a price increase of 317.14% is expected in the next year compared to the current price of 36.2. Check the SAREPTA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SAREPTA THERAPEUTICS INC worth?
SAREPTA THERAPEUTICS INC (SRPT) has a market capitalization of 3.56B USD. This makes SRPT a Mid Cap stock.
How many employees does SAREPTA THERAPEUTICS INC have?
SAREPTA THERAPEUTICS INC (SRPT) currently has 1372 employees.
What are the support and resistance levels for SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a resistance level at 57.01. Check the full technical report for a detailed analysis of SRPT support and resistance levels.
Is SAREPTA THERAPEUTICS INC (SRPT) expected to grow?
The Revenue of SAREPTA THERAPEUTICS INC (SRPT) is expected to grow by 47.83% in the next year. Check the estimates tab for more information on the SRPT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SAREPTA THERAPEUTICS INC (SRPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRPT, evaluating the profitability, health, valuation and growth aspects
- SAREPTA THERAPEUTICS INC (SRPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SAREPTA THERAPEUTICS INC (SRPT) Sales and EPS estimates to see what analysts future expectations are.
- SAREPTA THERAPEUTICS INC (SRPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SAREPTA THERAPEUTICS INC (SRPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- SAREPTA THERAPEUTICS INC (SRPT) Stock Chart to make your own analysis
- SAREPTA THERAPEUTICS INC (SRPT) Latest news and press-releases to stay up to date.
Does SAREPTA THERAPEUTICS INC (SRPT) stock pay dividends?
SRPT does not pay a dividend.
When does SAREPTA THERAPEUTICS INC (SRPT) report earnings?
SAREPTA THERAPEUTICS INC (SRPT) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of SAREPTA THERAPEUTICS INC (SRPT)?
SAREPTA THERAPEUTICS INC (SRPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
What is the Short Interest ratio of SAREPTA THERAPEUTICS INC (SRPT) stock?
The outstanding short interest for SAREPTA THERAPEUTICS INC (SRPT) is 7.21% of its float. Check the ownership tab for more information on the SRPT short interest.
SRPT Technical Analysis
SRPT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SRPT. Both the profitability and financial health of SRPT have multiple concerns.
SRPT Financial Highlights
Over the last trailing twelve months SRPT reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS decreased by -1472.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.17% | ||
| ROE | -21.74% | ||
| Debt/Equity | 1 |
SRPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SRPT. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 214.63% and a revenue growth 47.83% for SRPT